Literature DB >> 20404505

Hsp90 inhibitors: a potential treatment for latent EBV infection?

Xiaoping Sun1, Shannon C Kenney.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20404505      PMCID： PMC2879875          DOI： 10.4161/cc.9.9.11594

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  11 in total

1.  Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1.

Authors:  Yili Yin; Bénédicte Manoury; Robin Fåhraeus
Journal:  Science       Date:  2003-09-05       Impact factor: 47.728

2.  Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition.

Authors:  Judy Tellam; Corey Smith; Michael Rist; Natasha Webb; Leanne Cooper; Tony Vuocolo; Geoff Connolly; David C Tscharke; Michael P Devoy; Rajiv Khanna
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-30       Impact factor: 11.205

3.  Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism.

Authors:  Xiaoping Sun; Elizabeth A Barlow; Shidong Ma; Stacy R Hagemeier; Sarah J Duellman; Richard R Burgess; Judy Tellam; Rajiv Khanna; Shannon C Kenney
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-26       Impact factor: 11.205

4.  Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.

Authors:  J Levitskaya; A Sharipo; A Leonchiks; A Ciechanover; M G Masucci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

5.  Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone.

Authors:  C Prodromou; S M Roe; R O'Brien; J E Ladbury; P W Piper; L H Pearl
Journal:  Cell       Date:  1997-07-11       Impact factor: 41.582

Review 6.  The plasmid replicon of Epstein-Barr virus: mechanistic insights into efficient, licensed, extrachromosomal replication in human cells.

Authors:  Scott E Lindner; Bill Sugden
Journal:  Plasmid       Date:  2007-03-09       Impact factor: 3.466

7.  Interaction of Hsp90 with ribosomal proteins protects from ubiquitination and proteasome-dependent degradation.

Authors:  Tae-Sung Kim; Chang-Young Jang; Hag Dong Kim; Jae Yung Lee; Byung-Yoon Ahn; Joon Kim
Journal:  Mol Biol Cell       Date:  2005-11-28       Impact factor: 4.138

8.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.

Authors:  Adeela Kamal; Lia Thao; John Sensintaffar; Lin Zhang; Marcus F Boehm; Lawrence C Fritz; Francis J Burrows
Journal:  Nature       Date:  2003-09-25       Impact factor: 49.962

Review 9.  Purine-scaffold Hsp90 inhibitors.

Authors:  Tony Taldone; Gabriela Chiosis
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

Review 10.  Targeting Hsp90: small-molecule inhibitors and their clinical development.

Authors:  Tony Taldone; Alexander Gozman; Ronnie Maharaj; Gabriela Chiosis
Journal:  Curr Opin Pharmacol       Date:  2008-07-31       Impact factor: 5.547
View more
  5 in total

1.  Interactions between Hsp90 and oncogenic viruses: implications for viral cancer therapeutics.

Authors:  Michael R Defee; Zhiqiang Qin; Lu Dai; Jennifer S Isaacs; Chris H Parsons
Journal:  Am J Cancer Res       Date:  2011-06-05       Impact factor: 6.166

Review 2.  Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development.

Authors:  Qianya Wan; Dan Song; Huangcan Li; Ming-Liang He
Journal:  Signal Transduct Target Ther       Date:  2020-07-13

Review 3.  HSP90: chaperone-me-not.

Authors:  J M Patki; S S Pawar
Journal:  Pathol Oncol Res       Date:  2013-07-31       Impact factor: 3.201

4.  Utilising proteomic approaches to understand oncogenic human herpesviruses (Review).

Authors:  Christopher B Owen; David J Hughes; Belinda Baquero-Perez; Anja Berndt; Sophie Schumann; Brian R Jackson; Adrian Whitehouse
Journal:  Mol Clin Oncol       Date:  2014-07-09

Review 5.  EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers.

Authors:  Lijun Jiang; Chen Xie; Hong Lok Lung; Kwok Wai Lo; Ga-Lai Law; Nai-Ki Mak; Ka-Leung Wong
Journal:  Theranostics       Date:  2018-10-22       Impact factor: 11.556
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.